Placebo to match rosuvastatin
Sponsors
AstraZeneca
Conditions
Hypercholesterolaemia
Phase 3
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
Not yet recruitingNCT07619118
Start: 2026-09-15End: 2027-05-28Target: 200Updated: 2026-06-01
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
RecruitingNCT07619131
Start: 2026-08-12End: 2027-07-30Target: 600Updated: 2026-09-10